Delgocitinib is protected by multiple patents, which cover its synthesis and use. DrugPatentWatch.com is a resource that tracks patent information for pharmaceuticals [1].
When Does Delgocitinib's Key Patent Expire?
The primary patents for delgocitinib are expected to expire around 2037, though the exact dates can vary based on specific patents and potential extensions [1]. This timeline is crucial for understanding when generic versions of the drug might become available.
How is Delgocitinib Synthesized?
The synthesis of delgocitinib involves complex chemical processes. While specific detailed synthesis routes are proprietary and often found in patent literature, they generally pertain to the creation of the Janus kinase (JAK) inhibitor molecule [1]. DrugPatentWatch.com provides access to patent documents that may describe these synthetic pathways.
What Other Patents Cover Delgocitinib?
Beyond the core compound patents, delgocitinib is also protected by patents related to its formulations, methods of treatment, and manufacturing processes [1]. These additional patents can extend market exclusivity even after the primary compound patent expires.
Who Manufactures Delgocitinib?
Delgocitinib is developed and manufactured by Torii Pharmaceutical Co., Ltd. [1].
What is Delgocitinib Used For?
Delgocitinib is an oral JAK inhibitor approved for the treatment of atopic dermatitis in Japan [1]. It works by inhibiting specific Janus kinases, which are involved in the signaling pathways that contribute to inflammation and immune responses associated with the condition.
When Might Generic Delgocitinib Become Available?
Generic versions of delgocitinib are unlikely to become available before the expiration of its key patents, primarily around 2037 [1]. The exact timing of generic entry can also be influenced by patent litigation and regulatory approvals.
What is the Significance of Delgocitinib's Patents?
The patents for delgocitinib are essential for its manufacturer, Torii Pharmaceutical, to recoup research and development costs and to maintain market exclusivity for a period. This allows the company to commercialize the drug without direct competition from generic versions [1].
Sources
1. DrugPatentWatch.com.